Daiichi Sankyo

News

ASCO: Enhertu data sets up tumour-agnostic label bid

AstraZeneca and Daiichi Sankyo’s Enhertu is already gathering momentum as a treatment for HER2-positive and HER2-low breast, gastric, and lung cancer, but new data could b

News

Japanese pharmas sign up to use new AI supercomputer

Mitsui, NVIDIA's Tokyo-1 supercomputer, aims to turbocharge Japan’s use of AI in drug discovery

News

Esperion and Daiichi Sankyo square up on Nexletol milestone

Companies can't see eye to eye on the recently reported data from the CLEAR outcomes study.

News

Daiichi Sankyo wins round in Enhertu patent dispute

US PTO has agreed to take another look at whether Seagen's '039 patent is valid.

News

EU clears Enhertu for HER2-low breast cancer

The European Commission has approved Daiichi Sankyo and AstraZeneca's Enhertu as the first targeted therapy for HER2-low breast cancer, unlocking a large population of patients who could be

News

Packaged Pills in aluminium blisters stacked on each other

Japanese drugmakers make greener packaging pledge

Four Japanese drugmakers – Astellas, Eisai, Daiichi Sankyo, and Takeda – have joined forces in a partnership intended to reduce the environmental impact of pharmaceutical packaging.

ASCO: Enhertu data sets up tumour-agnostic label bid

Japanese pharmas sign up to use new AI supercomputer

Esperion and Daiichi Sankyo square up on Nexletol milestone

Daiichi Sankyo wins round in Enhertu patent dispute

EU clears Enhertu for HER2-low breast cancer

Japanese drugmakers make greener packaging pledge

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Daiichi Sankyo

Editor's Picks